Authors: STINGL G BROCKER EB MERTELSMANN R WOLFF K SCHREIBER S KAMPGEN E SCHNEEBERGER A TRCKA J BRENNSCHEIDT U VEELKEN H BIRNSTIEL ML ZATLOUKAL K MAASS G WAGNER E BUSCHLE M KEMPE ER WEBER HA VOIGT T

Citation: G. Stingl et al., PHASE-I STUDY TO THE IMMUNOTHERAPY OF METASTATIC MALIGNANT-MELANOMA BY A CANCER VACCINE CONSISTING OF AUTOLOGOUS CANCER-CELLS TRANSFECTED WITH THE HUMAN IL-2 GENE, Journal of molecular medicine, 75(4), 1997, pp. 297-299

Authors: STINGL G BROCKER EB MERTELSMANN R WOLFF K SCHREIBER S KAMPGEN E SCHNEEBERGER A DUMMER W BRENNSCHEID U VEELKEN H BIRNSTIEL ML ZATLOUKAL K SCHMIDT W MAASS G WAGNER E BUSCHLE M GIESE M KEMPE ER WEBER HA VOIGT T

Citation: G. Stingl et al., PHASE-I STUDY TO THE IMMUNOTHERAPY OF METASTATIC MALIGNANT-MELANOMA BY A CANCER VACCINE CONSISTING OF AUTOLOGOUS CANCER-CELLS TRANSFECTED WITH THE HUMAN IL-2 GENE, Human gene therapy, 7(4), 1996, pp. 551-563

Authors: DIEZEL W WEBER HA MACIEJEWSKI J VOLK HD

Citation: W. Diezel et al., THE EFFECT OF SPLENOPENTIN (DA-SP-5) ON INVITRO MYELOPOIESIS AND ON AZT-INDUCED BONE-MARROW TOXICITY, International journal of immunopharmacology, 15(3), 1993, pp. 269-273